[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatocellular-carcinoma-stage-iv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatocellular-carcinoma-stage-iv":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100515493","phase-2-atezolizumab-plus-bevacizumab-alone-or-combined-with-external-beam-radiotherapy-for-hcc-with-macrovascular-invasion-100515493",false,"NCT05992220","Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion","A Randomized, Multicenter, Open-Label, Phase II Trial of Atezolizumab Plus Bevacizumab Alone or Combined with External Beam RadioTherapy for HepatoCellular Carcinoma with Macrovascular Invasion (ALERT-HCC)","ALERT-HCC","Inclusion Criteria:\n\n* Older than 19 years of age, lower than 80 years of age\n* Child-Pugh class A hepatic function\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1\n* Patients with HCC \\[diagnosed according to AASLD guidelines\\] invading the intrahepatic vascular system\n* No prior systemic therapy for HCC\n* At least one measurable HCC lesion with ≥ 1cm diameter\n* Adequate hematologic and organ function\n\n  * Hemoglobin ≥ 9.0 g\u002FdL\n  * Absolute neutrophil count ≥ 1,000 \u002Fmm3\n  * Platelet ≥ 50,000\u002F mm3 without transfusion\n* Total bilirubin ≤ 2.5 mg\u002FdL\n\nExclusion Criteria:\n\n* Treatment history of prior systemic treatment of HCC\n* Liver transplant recipients\n* Patients with peptic ulcer, untreated or incompletely treated varices with bleeding or high-risk for bleeding\n* Any serious illness (e.g., active infection or inflammatory condition) or uncontrolled severe medical comorbidity\n* A history of treated malignancy (other than HCC) is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding two years\n* Abdominal\u002Fpelvic radiotherapy within 28 days prior to initiation of study treatment, except palliative radiotherapy to bone lesions within 7 days prior to initiation of study treatment","ALL","20 Years","79 Years",{"count":21,"type":22},138,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The recent global IMbrave150 study evaluated the combination of atezolizumab and bevacizumab versus sorafenib in 501 patients with advanced or metastatic Hepatocellular Carcinoma (HCC). The median overall survival (OS) was notably better in the atezolizumab\u002Fbevacizumab group. However, for HCC patients with intrahepatic macrovascular invasion (MVI), the prognosis remains poor, indicating a significant unmet need in this group.\n\nExternal Beam Radiotherapy (EBRT) has shown promising results in treating HCC with MVI, especially when used in combination with trans-arterial chemoembolization (TACE). It has been reported that radiotherapy may make tumor cells more susceptible to immune-mediated therapy, potentially enhancing the effects of atezolizumab and bevacizumab.\n\nThus, this study aims to investigate the efficacy and safety of atezolizumab\u002Fbevacizumab alone versus atezolizumab\u002Fbevacizumab in combination with EBRT in HCC patients with macrovascular invasion.",[28,29,30,31,32],"Hepatocellular Carcinoma","Hepatocellular Cancer","Hepatocellular Carcinoma Non-resectable","Hepatocellular Carcinoma Stage IV","Liver Cancer",[34],"HCC; vascular invasion; portal vein tumor thrombosis; BCLC stage C","RECRUITING","2025-02-19",{"date":38,"type":39},"2025-02-21","ACTUAL",{"date":41,"type":39},"2022-10-22",{"date":43,"type":22},"2026-03",{"name":45,"class":46},"Asan Medical Center","OTHER"]